1 Tempero, M. A. NCCN Guidelines Updates: Pancreatic Cancer. J. Natl. Compr. Canc. Netw. 17, 603-605, doi:10.6004/jnccn.2019.5007 (2019).
2 Sohal, D. P. S. et al. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. J. Clin. Oncol. 36, 2545-2556, doi:10.1200/JCO.2018.78.9636 (2018).
3 Ducreux, M. et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26 Suppl 5, v56-68, doi:10.1093/annonc/mdv295 (2015).
4 Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691-1703, doi:10.1056/NEJMoa1304369 (2013).
5 Loprinzi, C. L. et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J. Clin. Oncol. 38, 3325-3348, doi:10.1200/JCO.20.01399 (2020).
6 Dorsey, S. G. et al. The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. J. Natl. Cancer Inst. 111, 531-537, doi:10.1093/jnci/djz011 (2019).
7 Domon, Y. et al. Binding Characteristics and Analgesic Effects of Mirogabalin, a Novel Ligand for the alpha2delta Subunit of Voltage-Gated Calcium Channels. J Pharmacol Exp Ther 365, 573-582, doi:10.1124/jpet.117.247551 (2018).
8 Kato, J. et al. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain 160, 1175-1185, doi:10.1097/j.pain.0000000000001501 (2019).
9 Baba, M., Matsui, N., Kuroha, M., Wasaki, Y. & Ohwada, S. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig 10, 1299-1306, doi:10.1111/jdi.13013 (2019).
10 Okusaka, T. et al. Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis. Pancreas 49, 326-335, doi:10.1097/MPA.0000000000001513 (2020).
11 Salehifar, E. et al. Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial. Clin. Drug Investig. 40, 249-257, doi:10.1007/s40261-019-00882-6 (2020).
12 Cavaletti, G. et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur. J. Cancer 46, 479-494, doi:10.1016/j.ejca.2009.12.008 (2010).
13 Yoshida, Y. et al. The Relationship Between Evaluation Methods for Chemotherapy-Induced Peripheral Neuropathy. Sci. Rep. 9, 20361, doi:10.1038/s41598-019-56969-9 (2019).
14 Kato, J. et al. Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies. Clin. Ther., doi:10.1016/j.clinthera.2021.03.015 (2021).
15 Inage, K. et al. Frequency of Adverse Drug Reactions and Analgesic Effects of Mirogabalin during Treatment of Peripheral Neuropathic Pain: A Retrospective Clinical Investigation. Spine Surg Relat Res 4, 354-357, doi:10.22603/ssrr.2020-0042 (2020).
16 Ueno, H. et al. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 77, 595-603, doi:10.1007/s00280-016-2972-3 (2016).